SCHEMBL19425474

SCHEMBL19425474

O=C(O)C(Cc1ccccc1)N1CS/C(=C/c2ccco2)C1=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 9/20 0.52
▸ ALDH1A1 P00352 8/20 0.52
▸ MEN1 O00255 8/20 0.52
▸ KMT2A Q03164 8/20 0.52
▸ POLB P06746 6/20 0.52
▸ RECQL P46063 4/20 0.52
▸ KDM4E B2RXH2 4/20 0.52
▸ L3MBTL1 Q9Y468 4/20 0.52
▸ TDP1 Q9NUW8 3/20 0.52
▸ THRB P10828 3/20 0.52
▸ USP2 O75604 2/20 0.52
▸ PSMD14 O00487 1/20 0.52
▸ MMP2 P08253 1/20 0.52
▸ BLM P54132 1/20 0.52
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ LMNA P02545 2/20 0.46
▸ ALOX12 P18054 1/20 0.46
▸ ALOX15 P16050 1/20 0.45
▸ MME P08473 2/20 0.41
▸ PKM P14618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20705618 0.79 MAPT (0.63) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL14680251 0.77 MAPT (0.78) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL15502362 0.72 MAPT (0.56) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL26458902 0.68 MAPT (1.00) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL14680220 0.68 MAPT (1.00) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL9074064 0.64 ALDH1A1 (0.63) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL19621077 0.64 ALDH1A1 (0.63) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL6571504 0.64 ALDH1A1 (0.63) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL20705581 0.64 MAPT (0.67) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL908487 0.63 LMNA (0.55) MAPTALDH1A1MEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170281649-A1 COMPOUNDS AND THERAPEUTIC USES UNITY BIOTECHNOLOGY, INC. 2017-10-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170281649-A1 COMPOUNDS AND THERAPEUTIC USES TP53, NQO1, SHMT2 MAPT 1762/4885ALDH1A1 545/4885MEN1 3416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback